Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACAD is in the long-term up 880% in 15 years.
Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-2.61||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-85.71%||Sales Growth - Q/Q||-91.67%||P/E||-10.38|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-38.09%||ROE||-40.35%||ROI|
|Current Ratio||18.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||-123217%||Net Profit Margin||-122364%||Dividend Payout Ratio|
|Cash From Financing Activities||1.44 M||Cash From Investing Activities||38.47 M||Cash From Operating Activities||-25.35 M||Gross Profit|
|Net Profit||-40.38 M||Operating Profit||-40.55 M||Total Assets||301.96 M||Total Current Assets||299.9 M|
|Total Current Liabilities||16.65 M||Total Debt||Total Liabilities||16.87 M||Total Revenue|
|High 52 week||39.14||Low 52 week||15.12||Last close||17.87||Last change||1.53%|
|RSI||52.92||Average true range||0.66||Beta||1.75||Volume||3.38 M|
|Simple moving average 20 days||0.08%||Simple moving average 50 days||-2.47%||Simple moving average 200 days||-35.73%|
|Performance Week||2.47%||Performance Month||-2.14%||Performance Quart||-30.98%||Performance Half||-40.61%|
|Performance Year||-34.78%||Performance Year-to-date||-40.65%||Volatility daily||1.95%||Volatility weekly||4.36%|
|Volatility monthly||8.94%||Volatility yearly||30.98%||Relative Volume||1230.89%||Average Volume||2.95 M|
|New High||New Low|
2019-11-18 10:17:03 | Medtronic MDT to Report Q2 Earnings: What's in Store?
2019-11-12 08:18:01 | The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
2019-11-11 16:48:26 | IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity
2019-11-11 09:28:02 | 4 Biotech Stocks That Could Keep Beating Wall Street
2019-11-07 05:13:59 | Have Insiders Been Selling ACADIA Pharmaceuticals Inc. NASDAQ:ACAD Shares?
2019-11-06 10:00:03 | What Makes Acadia Pharmaceuticals ACAD a Strong Momentum Stock: Buy Now?
2019-11-06 09:00:02 | Acadia ACAD Upgraded to Buy: Here's Why
2019-11-03 15:03:24 | Edited Transcript of ACAD earnings conference call or presentation 30-Oct-19 8:30pm GMT
2019-10-30 19:25:11 | Acadia Pharmaceuticals ACAD Reports Q3 Loss, Tops Revenue Estimates
2019-10-30 16:05:00 | ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
2019-10-29 08:46:12 | Cigna CI to Report Q3 Earnings: What's in the Offing?
2019-10-28 11:22:03 | Teladoc TDOC to Report Q3 Earnings: What's in the Cards?
2019-10-25 12:12:04 | Will Nuplazid Aid Growth for ACADIA ACAD in Q3 Earnings?
2019-10-24 16:58:59 | Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. ACAD Again
2019-10-09 11:18:03 | Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
2019-10-08 06:00:00 | Acadia Sees Strong Results in Dementia Treatment
2019-10-03 16:55:00 | ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease CTAD 2019 Meeting
2019-10-02 06:37:50 | We Think ACADIA Pharmaceuticals NASDAQ:ACAD Can Easily Afford To Drive Business Growth
2019-09-26 09:14:01 | Should First Trust Mid Cap Growth AlphaDEX Fund FNY Be on Your Investing Radar?
2019-09-24 16:05:00 | ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
2019-09-20 13:10:14 | Gilead, AbbVie Are Innovative, but May Be Underappreciated
2019-09-17 23:00:00 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock
2019-09-17 16:02:00 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
2019-09-17 15:25:42 | 5 Top Stock Trades for Wednesday: BA, ACB, PINS
2019-09-11 10:23:43 | 3 Hot Biotechs with High Upside Potential
2019-09-10 11:41:03 | ACADIA Surges on Early Success of Nuplazid Dementia Study
2019-09-10 10:59:02 | Will ACADIA Continue to Surge Higher?
2019-09-10 08:39:00 | Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?
2019-09-09 17:38:00 | Why Acadia Pharmaceuticals Stock Skyrocketed Today
2019-09-09 16:55:24 | ACADIA Pharmaceuticals Help Lift Biotech ETFs
2019-09-09 16:26:30 | Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High
2019-09-09 16:13:00 | What Happened in the Stock Market Today
2019-09-09 12:17:30 | A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019
2019-09-09 10:26:18 | Options Hot as ACADIA Pharmaceuticals Stock Soars
2019-09-09 09:05:01 | ACADIA Enters Oversold Territory
2019-09-09 07:31:00 | [video]Acadia Pharmaceuticals Surges on Positive Trial Results for Psychosis Treatment